Media
Press Release
Revolution Medicines to Present Preclinical Data on Novel Inhibitors of Oncogenic RAS(ON) Mutants at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
REDWOOD CITY, CA – October 22, 2019 – Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced that preclinical in…
Read morePublication / Presentation
Press Release
REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor
REDWOOD CITY, CA – September 17, 2019 – REVOLUTION Medicines, Inc., a clinical-stage oncology company focused on developing novel targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced dosing of the…
Read morePublication / Presentation
Publication / Presentation
News
Revolution Medicines snags $100M to attack RAS-mutated cancers
Revolution Medicines raised $100 million in series C financing to advance a stable of drugs aiming at what it calls “frontier targets” in cancer. These include a program targeting KRAS mutations, which were previously considered undruggable.…
Read morePress Release
REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers
REDWOOD CITY, CA – July 9, 2019 – REVOLUTION Medicines, Inc., a clinical-stage leader in the discovery and development of novel small molecule inhibitors of frontier oncology targets within notorious pathways, today announced the closing of a $100…
Read moreNews
Abstract painter: ASCO's KRAS rollouts red Haring? Early brushwork pleases
Der, for his part, predicted clinical data would separate the pair better in terms of PK issues. He also highlighted early work by Redwood City, Calif.-based Revolution Medicines Inc., saying that the company’s effort “stands out from all the other…
Read more